Last updated date
ABOUT THIS STUDY
The purpose of this study is to estimate the local and systemic tolerability of Prevenar in
children ages 2 to 5 years old in usual care settings.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
2-5 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- High-risk children ages 2 to 5 years old
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Prior administration of Prevenar
- Prior and/or concurrent administration of 23 vPs vaccine
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Pneumococcal DiseaseSafety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
NCT04642079
- Chamblee, Georgia
- Sioux City, Iowa
- Binghamton, New York
- Dayton, Ohio
- Austin, Texas
- San Antonio, Texas
- Murray, Utah
- Provo, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- South Jordan, Utah
- Syracuse, Utah
- Charlottesville, Virginia
- Charlottesville, Virginia
- Charlottesville, Virginia
ALL GENDERS
15 Months+
years
MULTIPLE SITES
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
NCT04546425
- Milano, Milan
- Firenze,
- Foggia,
- Haarlem,
- Hoofddorp,
- Oslo,
- Westmead, New South Wales
- Nedlands, Western Australia
- Nedlands, Western Australia
- Brussels,
- Edegem,
- Jindrichuv Hradec,
- Jindrichuv Hradec,
- Jindrichuv Hradec,
- Pardubice,
- Praha 3,
- Praha 6,
- Sezemice,
- Tallinn,
- Tallinn,
- Tallinn,
- Tallinn,
- Tartu,
- Espoo,
- Helsinki,
- Helsinki,
- Järvenpää,
- Kokkola,
- Oulu,
- Pori,
- Seinajoki,
- Tampere,
- Turku,
- Bydgoszcz,
- Bydgoszcz,
- Debica,
- Krakow,
- Krakow,
- Leczna,
- Lodz,
- Lubon,
- Siemianowice Slaskie,
- Torun,
- Trzebnica,
- Warszawa,
- Warszawa,
- Wroclaw,
- Wroclaw,
- Bratislava,
- Bratislava,
- Detva,
- Horne Srnie,
- Humenne,
- Humenné,
- Kosice,
- Liptovská Osada,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
NCT04530838
- Isumi-city, Chiba
- Fukuoka-city, Fukuoka
- Fukuoka-shi, Fukuoka
- Osaka-City, Osaka
- Ritto-Shi, Shiga
- Nagoya-shi, Aichi
- Toyota-shi, Aichi
- Chiba-shi, Chiba
- Funabashi-city, Chiba
- Yotsukaido-shi, Chiba
- Yotsukaido-shi, Chiba
- Fukui-shi, Fukui
- Fukuoka-City, Fukuoka
- Fukuoka-city, Fukuoka
- Iizuka, Fukuoka
- Kasuga-city, Fukuoka
- Gifu-city, Gifu
- Ebetsu Shi, Hokkaido
- Sapporo shi, Hokkaido
- Sapporo, Hokkaido
- Akashi-City, Hyōgo
- Kawasaki-shi, Kanagawa
- Kumamoto Shi, Kumamoto
- Kumamoto-shi, Kumamoto
- Kuwana-city, MIE
- Nagano-shi, Nagano
- Kawachinagano, Osaka
- Ureshino-shi, Saga
- Hanyu-shi, Saitama
- Kumagaya-shi, Saitama
- Fuchu-city, Tokyo
- Nishitokyo-shi, Tokyo
- Setagaya-ku, Tokyo
- Setagaya-ku, Tokyo
- Shinjuku-ku, Tokyo
- Suginami-ku, Tokyo
- Kofu-city, Yamanashi
- Tsuru-shi, Yamanashi
ALL GENDERS
2 Months+
years
MULTIPLE SITES
Pneumococcal DiseaseSafety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
NCT04526574
- Miami Lakes, Florida
- Miami, Florida
- Wilmington, North Carolina
- Oklahoma City, Oklahoma
- Wauwatosa, Wisconsin
- Birmingham, Alabama
- Mobile, Alabama
- Chandler, Arizona
- Phoenix, Arizona
- Tempe, Arizona
- Redding, California
- San Diego, California
- San Diego, California
- Walnut Creek, California
- Coral Gables, Florida
- Crystal River, Florida
- Hialeah, Florida
- Jacksonville, Florida
- Miami, Florida
- Orlando, Florida
- Orlando, Florida
- Savannah, Georgia
- Stockbridge, Georgia
- Meridian, Idaho
- El Dorado, Kansas
- Wichita, Kansas
- Wichita, Kansas
- Metairie, Louisiana
- New Orleans, Louisiana
- Elkridge, Maryland
- Rockville, Maryland
- Saint Louis, Missouri
- Norfolk, Nebraska
- Omaha, Nebraska
- Las Vegas, Nevada
- Las Vegas, Nevada
- Binghamton, New York
- Endwell, New York
- Charlotte, North Carolina
- Greensboro, North Carolina
- Hickory, North Carolina
- Raleigh, North Carolina
- Raleigh, North Carolina
- Rocky Mount, North Carolina
- Rocky Mount, North Carolina
- Fargo, North Dakota
- Cincinnati, Ohio
- Cincinnati, Ohio
- Cleveland, Ohio
- Franklin, Ohio
- Warwick, Rhode Island
- Little River, South Carolina
- Mount Pleasant, South Carolina
- Bristol, Tennessee
- Nashville, Tennessee
- Austin, Texas
- Cedar Park, Texas
- Fort Worth, Texas
- Fort Worth, Texas
- Houston, Texas
- McKinney, Texas
- Pearland, Texas
- San Antonio, Texas
- Tomball, Texas
- Tomball, Texas
- Draper, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- South Jordan, Utah
- Norfolk, Virginia
- Richmond, Virginia
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | |||||||
|---|---|---|---|---|---|---|---|
| Brief Title | Study Evaluating Prevenar in High-Risk Children | ||||||
| Official Title | Prospective Post-Marketing Surveillance Study of Prevenar in High-Risk Children Aged 2 to 5 Years | ||||||
| Brief Summary | The purpose of this study is to estimate the local and systemic tolerability of Prevenar in children ages 2 to 5 years old in usual care settings. | ||||||
| Detailed Description | Not Provided | ||||||
| Study Type | Observational | ||||||
| Study Design | Time Perspective: Prospective | ||||||
| Target Follow-Up Duration | Not Provided | ||||||
| Biospecimen | Not Provided | ||||||
| Sampling Method | Not Provided | ||||||
| Study Population | Not Provided | ||||||
| Condition | Pneumococcal Disease | ||||||
| Intervention | Not Provided | ||||||
| Study Groups/Cohorts | Not Provided | ||||||
| Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
| Recruitment Information | |||||||
| Recruitment Status | Completed | ||||||
| Estimated Enrollment | 5000 | ||||||
| Original Enrollment | Same as current | ||||||
| Actual Study Completion Date | April 2007 | ||||||
| Primary Completion Date | Not Provided | ||||||
| Eligibility Criteria | Inclusion Criteria:
Exclusion criteria:
| ||||||
| Sex/Gender |
| ||||||
| Ages | 2 Years to 5 Years (Child) | ||||||
| Accepts Healthy Volunteers | Yes | ||||||
| Contacts | Contact information is only displayed when the study is recruiting subjects | ||||||
| Listed Location Countries | Germany | ||||||
| Removed Location Countries | |||||||
| Administrative Information | |||||||
| NCT Number | NCT00234338 | ||||||
| Other Study ID Numbers | 101850 | ||||||
| Has Data Monitoring Committee | Not Provided | ||||||
| U.S. FDA-regulated Product | Not Provided | ||||||
| IPD Sharing Statement | Not Provided | ||||||
| Responsible Party | Not Provided | ||||||
| Study Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer | ||||||
| Collaborators | Not Provided | ||||||
| Investigators |
| ||||||
| PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | ||||||
| Verification Date | December 2007 | ||||||